ROCHESTER, Minn. — Mayo Clinic is advancing its use of artificial intelligence with the implementation of the NVIDIA DGX SuperPOD and DGX B200 systems to enhance healthcare innovations.
The collaboration between Mayo Clinic and NVIDIA focuses on developing AI models that align with Mayo’s Bold. Forward. strategy, aiming to improve patient outcomes through early disease detection and innovative solutions in digital pathology.
“Our aspiration for AI is to meaningfully improve patient outcomes by detecting disease early enough to intervene,” said Matthew Callstrom, M.D., Ph.D., medical director of the Department of Strategy and leader of Mayo Clinic’s Generative Artificial Intelligence Program.
The new computing infrastructure will aid in the development of models for pathomics, drug discovery, and precision medicine. The NVIDIA Blackwell-powered system is designed to handle large, high-resolution imaging quickly, reducing processing time from four weeks to just one.
Mayo Clinicsays its partnership with Aignostics led to the creation of the Atlas pathology model, trained on over 1.2 million histopathology images, enhancing accuracy and reducing administrative tasks.
“This compute power, coupled with Mayo’s unparalleled clinical expertise and platform data of over 20 million digitized pathology slides, will allow Mayo to build on its existing foundation models,” said Jim Rogers, CEO of Mayo Clinic Digital Pathology.
Mayo Clinic says the initiative aims to transform healthcare by developing AI solutions that improve patient care and foster industry collaborations.